Sol-Gel Reports First Quarter 2025 Results
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025.
Financial Results for the First Quarter Year Ended March 31st, 2025
Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024.
Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. The increase of $3.5 million was primarily attributed to an increase of $3.6 million due to expenses associated with supplier-led manufacturing development to support future commercialization of SGT-610, an increase of $0.5 million related to the commercialization of EPSOLAY and TWYNEO in territories outside of the U.S., offset by a decrease of $0.5 million in clinical trial expenses related to SGT-610.
General and administrative expenses were $1.3 million compared to $1.8 million for the same period in 2024. The decrease of $0.5 million was mainly attributed to a decrease in payroll and stock-based compensation expenses due to cost measures being taken in 2024.
Sol-Gel reported a net loss of $8.8 million for the first quarter of 2025 and of $3.2 basic and diluted loss per share, compared to a net loss of $6.3 million and a loss of $2.3 per basic and diluted share for the same period in 2024.
As of March 31, 2025, Sol-Gel had $16.9 million in cash, cash equivalents, and deposits and no marketable securities for a total balance of $16.9 million.
The Company expects its cash resources to fund cash requirements into the first quarter of 2027.
About Sol-Gel Technologies
Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.
The Company's pipeline includes Orphan Drug candidate, SGT-610 under investigation for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and also includes topical drug candidate SGT-210 under investigation for the treatment of rare skin keratodermas.
For additional information, please visit www.sol-gel.com.
Forward Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to our expected cash runway. In some cases, you can identify forward-looking statements by terminology such as 'believe,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'expect,' 'predict,' 'potential,' or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management's current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, our ability to enter into further collaborations, lower than anticipated annual revenue income from new collaborations, a delay in the timing of our clinical trials, the success of our clinical trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators' ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaborators' ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators' ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and, (xvii) the current war between Israel and Hamas and any deterioration of the war in Israel into a broader regional conflict involving Israel with other parties. These factors and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ('SEC') on April 29, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.
SOL-GEL TECHNOLOGIES LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
(Unaudited)
December 31,
March 31,
2024
2025
Assets
CURRENT ASSETS:
Cash and cash equivalents
$
19,489
$
16,890
Bank deposits
12
12
Marketable securities
4,425
-
Accounts receivables
3,595
3,883
Prepaid expenses and other current assets
3,774
2,647
TOTAL CURRENT ASSETS
31,295
23,432
NON-CURRENT ASSETS:
Restricted long-term deposits and cash equivalents
1,291
1,293
Long-term receivables
1,024
518
Property and equipment, net
202
183
Operating lease right-of-use assets
1,426
1,332
Other long-term assets
13
-
Funds in respect of employee rights upon retirement
595
305
TOTAL NON-CURRENT ASSETS
4,551
3,631
TOTAL ASSETS
$
35,846
$
27,063
Liabilities and shareholders' equity
CURRENT LIABILITIES:
Accounts payable
$
1,265
$
438
Other accounts payable
3,590
3,702
Current maturities of operating leases
430
433
TOTAL CURRENT LIABILITIES
5,285
4,573
LONG-TERM LIABILITIES:
Operating leases liabilities
878
746
Liability for employee rights upon retirement
833
363
Other long-term Liability
1,209
TOTAL LONG-TERM LIABILITIES
1,711
2,318
TOTAL LIABILITIES
6,996
6,891
SHAREHOLDERS' EQUITY:
Ordinary shares, NIS 0.1 par value – authorized: 5,000,000 as of December 31,
2024 and March 31, 2025, respectively; issued and outstanding: 2,785,762 as of December 31, 2024 and March 31, 2025, respectively (*)
774
774
Additional paid-in capital
258,959
259,089
Accumulated deficit
(230,883)
(239,691)
TOTAL SHAREHOLDERS' EQUITY
28,850
20,172
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
$
35,846
$
27,063
(*) All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split.
SOL-GEL TECHNOLOGIES LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands)
(Unaudited)
Three months endedMarch 31
2024
2025
LICENSE REVENUES
$
466
$
1,031
RESEARCH AND DEVELOPMENT EXPENSES
5,345
8,843
GENERAL AND ADMINISTRATIVE EXPENSES
1,833
1,257
OPERATING LOSS
6,712
9,069
FINANCIAL INCOME,net
(368)
(261)
LOSS FOR THE PERIOD
6,344
8,808
BASIC AND DILUTED LOSS PER ORDINARY SHARE
2.3
3.2
WEIGHTED AVERAGE NUMBER OF
SHARES*OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (*)
2,785,762
2,785,762
(*)All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split.
Sol-Gel Contact:Eyal Ben-OrChief Financial Officerir@sol-gel.com+972-8-9313429Source: Sol-Gel Technologies Ltd.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia
CoreWeave has made a splash in the market as it quickly grows its cloud services business. Nvidia is proving its AI lineup of products is becoming more and more pervasive. CoreWeave is valued at a high multiple and has massive capital spending planned. 10 stocks we like better than Nvidia › There will prove to be many winners as artificial intelligence (AI) infrastructure continues to grow and AI end-uses expand. Nvidia (NASDAQ: NVDA) has been the Wall Street darling surrounding everything AI for the past two years. CoreWeave (NASDAQ: CRWV) has been getting the love most recently, though. Shares of the AI hyperscaler providing cloud services have soared about 185% in just the past month as of this writing. Nvidia stock has increased 24% in that time. CoreWeave just went public in late March, and the shares have jumped about 270% since that initial public offering (IPO). Investors may wonder if Nvidia's shine is fading, and it's time to buy CoreWeave instead. I'd argue that is flawed thinking, however. Investors may be taking a breather after the early exponential gains in Nvidia stock. Growth in the business itself has also slowed, though that was inevitable. Sales of its advanced chips in the data center segment had been growing like a weed. Revenue in that segment has been increasing in each consecutive quarter for the last two years. In the most recent fiscal quarter, that growth rate slowed to 10%, though, as seen below. Despite that trend, it's clear AI demand hasn't yet peaked. Remember, these are still sequential quarterly increases in data center sales. For perspective, that fiscal first-quarter revenue was a 73% jump compared to the prior year period. Management also guided investors to expect further revenue growth in the current quarter. So, while an unsustainable growth rate slows, the company is still solidly in growth mode. That's because it's not just Nvidia's advanced GPU and CPU chips driving sales and expanding AI infrastructure. Its AI ecosystem includes interconnect technologies, the CUDA (compute unified device architecture) software platform, and artificial intelligence processors that are part of many different types of architectures. CEO Jensen Huang recently touted Nintendo's new Switch 2 gaming console, for example. The unit includes Nvidia's AI processors that Huang claims "sharpen, animate, and enhance gameplay in real time." Nvidia has a broad array of customers. As AI factories and data centers are built, it will continue to be a major supplier and one that investors should benefit from owning. Nvidia also invests in the AI sector. It makes sense to look at where the AI leader itself sees future gains. One of the AI companies in which Nvidia holds a stake is CoreWeave. Nvidia should know CoreWeave well, too, as an important customer. CoreWeave leases data center space to companies needing the scalable, on-demand compute power it has control of from the 250,000 Nvidia chips it has purchased. It's a desirable option for enterprises that require significant computational power to process large amounts of data efficiently. There appears to be plenty of demand. But there is plenty of risk for investors, too. It just announced a new lease agreement to further increase capacity. Applied Digital, a builder and operator of purpose-built data centers, has agreed to deliver CoreWeave 250 megawatts (MW) of power load on a 15-year term lease at its recently built North Dakota data center campus. CoreWeave has the option to expand the load by an additional 150 MW in the future. Demand is quickly driving growth for CoreWeave. That's led investors to jump in and drive the stock higher in recent months. Valuation is just one major risk with CoreWeave. Customer concentration is another. Last year, Microsoft accounted for nearly two-thirds of revenue. CoreWeave also disclosed that 77% of 2024 revenue came from just its top two customers. CoreWeave is also spending massive amounts of capital to grow AI cloud capacity. It had about $5.4 billion of liquidity available as of March 31 and raised another $2 billion from a late May debt offering. That's approximately its level of capital expenditure in just the first quarter alone, though. That spending may pay off. But there are risks there as well. Customers could develop their own AI infrastructure or could redesign systems that don't require its services. CoreWeave stock also trades at a high valuation after the stock has soared. It recently had a price-to-sales (P/S) ratio of about 30. That could be cut in half this year with its strong sales growth, but it isn't earning any money yet. At the same time, Nvidia sports a price-to-earnings (P/E) ratio of about 30 based on this year's expected profits. Remember, too, that as CoreWeave grows, so do Nvidia's profits. Applied Digital CEO Wes Cummins said that its leased North Dakota data center campus will be full of Nvidia Blackwell class servers. I think the risk profile, financial picture, and massive potential for Nvidia make it the better AI stock to buy now. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Howard Smith has positions in Microsoft and Nvidia. The Motley Fool has positions in and recommends Microsoft and Nvidia. The Motley Fool recommends Nintendo and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Could Buying Tesla Stock Today Set You Up for Life?
Most of the value in Tesla lies in its robotaxi and full self-driving offerings. The company starts with a significant advantage over its competition, and is about to launch its robotaxi concept. Tesla is a speculative growth stock, but it has numerous advantages over the typical growth stock. These 10 stocks could mint the next wave of millionaires › For many investors, buying Tesla (NASDAQ: TSLA) has already set them up for life, but will that be true for anyone newly buying into the stock now? Here's a look at what you need to know before buying the stock. Tesla is an unusual stock, known to most investors primarily as the leading electric vehicle (EV) company, but that isn't the primary value driver of the stock. Indeed, if you look at Tesla solely as a car company, you would likely avoid the stock. Let's put it this way: Tesla currently trades at a price-to-earnings multiple of 192, compared to single-digit multiples at car companies like Ford Motor Company and General Motors. The valuation discrepancy doesn't stem from Tesla's superior profit margins or its leading position in the electric vehicle market. Instead, it comes down to Tesla being able to do something that rival car companies haven't yet done or have abandoned trying to do: launch a robotaxi service. General Motors has already abandoned robotaxi development, and Ford (which had planned to have a robotaxi service in place by 2021) ended its investment (alongside Volkswagen) in robotaxi company Argo AI in 2022. Volkswagen plans to launch its robotaxi service in 2026. So, if Tesla's valuation isn't justified in terms of being a highly successful electric vehicle company, then how should it be viewed? The following key points apply, and they make Tesla a highly attractive stock for the speculative end of your portfolio: The value in Tesla lies in its robotaxi business; this is not purely a car company stock, or even an electric vehicle stock, and its valuation reflects that. The reliance on robotaxi/full self-driving (FSD) makes it a speculative growth stock. Tesla's installed base of vehicles gives it significant advantages over Waymo and others. Tesla is not your average speculative growth stock; it holds significant advantages over typical growth stocks. The robotaxi concept and the FSD that powers it are potentially a huge earnings driver for Tesla. One of Tesla's most vocal and visible supporters, Cathie Wood's Ark Invest, which expected a valuation of $2,600 per share for Tesla in 2029, relies on a model that prescribes 88% of the company's value from robotaxis, compared to just 9% from EVs. The opportunity to earn recurring revenue from selling unsupervised FSD subscriptions to Tesla owners wanting to use their vehicles as robotaxis is massive, as is the potential to generate recurring revenue on a ride-per-mile basis from robotaxis. Moreover, Tesla plans to mass-produce its dedicated robotaxi vehicle, Cybercab, next year. That said, the robotaxi launch hasn't even taken place yet (it's scheduled for June 12 in Austin), and it will only be on a small scale initially. As such, Tesla is a speculative growth stock, an observation that suggests Tesla stock should be filed on a long list of highly speculative investments to consider on a rainy day. However, there are differences -- in fact, many differences -- between Tesla and typical growth stocks. First, speculative growth stocks are usually not established leaders in the core business that underpins their growth. The Model Y is not only the best-selling electric vehicle (EV) in the world, but it's also the best-selling car in the world. In other words, Tesla already has a compelling brand and is the market leader in the growth area of the auto market. Second, this is not a struggling small-cap stock desperately trying to establish brand recognition and promote its new technology to a sceptical marketplace. Waymo has offered a robotaxi service since 2018, and there is little doubt that consumers want to use robotaxis. Third, Tesla isn't a growth stock struggling with its finances and seeking a larger partner to invest, which would dilute existing shareholders' claims on future cash flows. A quick look at its most recent balance sheet reveals $37 billion in cash and equivalents, alongside $7.5 billion in debt and finance leases, resulting in a net cash position of $29.5 billion. Finally, Tesla's position as a cost-effective automaker with the capacity and scale to ramp up production and the vehicles on the road means it can produce robotaxis (whether Cybercab or existing Tesla models) to support growth, and it has a vast bank of data from Tesla vehicles to use to improve its FSD capability. All told, Tesla is speculative because its robotaxis haven't even been launched yet, there's a lot more certainty around the company than in most growth stocks. That makes it worth buying for the risk-seeking end of a portfolio. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $367,516!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,712!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $669,517!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 2, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends General Motors and Volkswagen Ag. The Motley Fool has a disclosure policy. Could Buying Tesla Stock Today Set You Up for Life? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
Upcoming Stock Splits This Week (June 9 to June 13)
These are the upcoming stock splits for the week of June 9 to June 13, based on TipRanks' Stock Splits Calendar. A stock split is a corporate maneuver that increases the number of shares outstanding by issuing more shares to existing holders, all while keeping the company's total market value unchanged. This lowers the price per share, often making the stock more affordable and potentially more appealing to retail investors. Confident Investing Starts Here: In contrast, a reverse stock split reduces the number of shares by consolidating them, which raises the price per share without affecting the company's valuation. Companies typically turn to this strategy to meet stock exchange requirements – like Nasdaq's minimum price threshold – and avoid delisting. Whether intended to boost investor interest or maintain compliance with exchange rules, these adjustments often serve as key signals for traders tracking a company's strategic direction. Let's take a look at the upcoming stock splits for the week. Nektar Therapeutics (NKTR) – Nektar Therapeutics is a biopharmaceutical company developing novel drug candidates. Following stockholder approval on May 23, the company formalized a 1-for-15 reverse stock split. The split takes effect on June 8, with trading on a split‑adjusted basis beginning June 9. Fangdd Network Group (DUO) – China-based Fangdd is a technology-driven real estate platform. The company confirmed a 16-for-1 reverse share consolidation, effective June 9, aimed at boosting its share price and maintaining compliance with listing standards. Bone Biologics (BBLG) – Bone Biologics develops orthobiologic products for spinal fusion procedures. After gaining shareholder approval on May 30, the company filed for a 1-for-6 reverse stock split, which takes effect on June 10. The goal is to elevate its share price back into compliance with Nasdaq's minimum pricing rules and enhance its appeal to institutional investors. Cero Therapeutics Holdings (CERO) – Cero Therapeutics is a biotech firm developing engineered T-cell immunotherapies for cancer. Following shareholder approval in November and board action on December 25, it enacted a 1-for-100 reverse stock split effective on January 8, consolidating every 100 shares into one. The move aimed to boost the stock above $1.00 and secure compliance with Nasdaq's listing standards. Inuvo, Inc. (INUV) – Inuvo specializes in AI-powered marketing technologies and is gearing up for a 1-for-10 reverse stock split on June 10. The move is designed to lift its share price, restore Nasdaq compliance, and strengthen its financial foundation for future growth. O'Reilly Automotive (ORLY) – O'Reilly Automotive is a specialty retailer of automotive aftermarket parts and accessories. On March 13, the company declared a 15-for-1 forward stock split, with the distribution of additional shares set for June 9 and split-adjusted trading beginning June 10. SaverOne 2014 (SVRE) – Israel-based SaverOne develops driver safety systems that block mobile-device distractions in vehicles. The company executed a 1-for-3 reverse ADS split, effective June 11, adjusting its American Depositary Share ratio to strengthen its Nasdaq standing and enhance market appeal. China Natural Resources, Inc. (CHNR) – China Natural Resources is focused on mining exploration in Inner Mongolia and is working toward picking up Zimbabwe's Williams Minerals lithium mine for up to $1.75 billion. The company executed an 8-for-1 reverse stock split effective June 12 to meet Nasdaq's $1 minimum bid price requirement, converting every eight shares into one to boost its per-share value and comply with listing rules
